HuperzineacompoundfortreatmentofAlzheimersdisease
- 經濟部產業技術司–專利資料集 @ 經濟部
專利名稱-中文HuperzineacompoundfortreatmentofAlzheimersdisease的核准國家是美國, 執行單位是工研院生醫所, 產出年度是101, 專利性質是發明, 計畫名稱是標靶藥物研發及技術平台開發四年計畫, 專利發明人是李昂,黃振倉,洪集英, 證書號碼是8,097,726.
序號 | 9137 |
產出年度 | 101 |
領域別 | 生技醫藥 |
專利名稱-中文 | HuperzineacompoundfortreatmentofAlzheimersdisease |
執行單位 | 工研院生醫所 |
產出單位 | 工研院生醫所 |
計畫名稱 | 標靶藥物研發及技術平台開發四年計畫 |
專利發明人 | 李昂,黃振倉,洪集英 |
核准國家 | 美國 |
獲證日期 | 101/03/08 |
證書號碼 | 8,097,726 |
專利期間起 | 101/01/17 |
專利期間訖 | 119/01/29 |
專利性質 | 發明 |
技術摘要-中文 | AhuperzineAcompound.ThehuperzineAcompoundhasfollowingformula:whereinisasingleordoublebond,R1andR2areindependentlyselectedfromthegroupconsistingofnull,hydrogen,-CR5R6-O-R7,-CR5R6-O-CO-R7,-CR5R6-O-CO-O-R7,-CR5R6-O-CO-NR8-R7,-CO-R7,-CO-O-R7and-CO-NR8-R7,andR3andR4togetherformaorindependentlyselectedfromthegroupconsistingofnull,hydrogen,-CO-O-CR5R6-O-R7,-CO-O-CR5R6-O-CO-R7,-CO-O-CR5R6-O-CO-O-R7,-CO-O-CR5R6-O-CO-NR8-R7,and,whereinR5,R6,R7,R8,andR17areindependentlyselectedfromthegroupconsistingofnull,hydrogen,C1-C32alkyl,C1-C32alkenyl,C1-C32alkynyl,C1-C32arylandC1-C32heteroaryl,andR9,R10,R11,R12,R13,R14,R15,andR16areindependentlyselectedfromthegroupconsistingofnull,hydrogen,halogen,hydroxyl,alkoxy,aryloxyl,amino,alkylamino,arylamino,dialkylamino,diarylamino,imino,alkylimino,arylimino,acylamido,diacylamido,acylimido,cyano,nitro,mercapto,carbamido,carbamoyl,carboxyl,thioureido,thiocyanato,sulfonamido,thio,sulfonyl,sulfinyl,C1-C32alkyl,C1-C32alkenyl,C1-C32alkynyl,C1-C32arylandC1-C32heteroaryl. |
技術摘要-英文 | (空) |
聯絡人員 | 李露頻 |
電話 | 03-5917812 |
傳真 | 03-5917431 |
電子信箱 | oralp@itri.org.tw |
參考網址 | http://www.itri.org.tw |
備註 | (空) |
特殊情形 | (空) |
同步更新日期 | 2023-07-05 |
序號9137 |
產出年度101 |
領域別生技醫藥 |
專利名稱-中文HuperzineacompoundfortreatmentofAlzheimersdisease |
執行單位工研院生醫所 |
產出單位工研院生醫所 |
計畫名稱標靶藥物研發及技術平台開發四年計畫 |
專利發明人李昂,黃振倉,洪集英 |
核准國家美國 |
獲證日期101/03/08 |
證書號碼8,097,726 |
專利期間起101/01/17 |
專利期間訖119/01/29 |
專利性質發明 |
技術摘要-中文AhuperzineAcompound.ThehuperzineAcompoundhasfollowingformula:whereinisasingleordoublebond,R1andR2areindependentlyselectedfromthegroupconsistingofnull,hydrogen,-CR5R6-O-R7,-CR5R6-O-CO-R7,-CR5R6-O-CO-O-R7,-CR5R6-O-CO-NR8-R7,-CO-R7,-CO-O-R7and-CO-NR8-R7,andR3andR4togetherformaorindependentlyselectedfromthegroupconsistingofnull,hydrogen,-CO-O-CR5R6-O-R7,-CO-O-CR5R6-O-CO-R7,-CO-O-CR5R6-O-CO-O-R7,-CO-O-CR5R6-O-CO-NR8-R7,and,whereinR5,R6,R7,R8,andR17areindependentlyselectedfromthegroupconsistingofnull,hydrogen,C1-C32alkyl,C1-C32alkenyl,C1-C32alkynyl,C1-C32arylandC1-C32heteroaryl,andR9,R10,R11,R12,R13,R14,R15,andR16areindependentlyselectedfromthegroupconsistingofnull,hydrogen,halogen,hydroxyl,alkoxy,aryloxyl,amino,alkylamino,arylamino,dialkylamino,diarylamino,imino,alkylimino,arylimino,acylamido,diacylamido,acylimido,cyano,nitro,mercapto,carbamido,carbamoyl,carboxyl,thioureido,thiocyanato,sulfonamido,thio,sulfonyl,sulfinyl,C1-C32alkyl,C1-C32alkenyl,C1-C32alkynyl,C1-C32arylandC1-C32heteroaryl. |
技術摘要-英文(空) |
聯絡人員李露頻 |
電話03-5917812 |
傳真03-5917431 |
電子信箱oralp@itri.org.tw |
參考網址http://www.itri.org.tw |
備註(空) |
特殊情形(空) |
同步更新日期2023-07-05 |